Comparing three medications for treating vertigo in the emergency department
Comparison of Efficacy of Metoclopramide , Promethazine and Prochloroperazine in the Treatment of Vertigo.
PHASE3 · Oman Medical Speciality Board · NCT05586763
This study is testing which of three medications works best to help adults with sudden vertigo feel better when they go to the emergency room.
Quick facts
| Phase | PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Oman Medical Speciality Board (other gov) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Muscat) |
| Trial ID | NCT05586763 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of three medications—metoclopramide, promethazine, and prochloroperazine—in treating patients with acute peripheral vertigo presenting to the emergency department. Conducted as a multi-center, randomized, triple-blind study, participants aged 18 to 60 will receive one of the three medications, which will be administered in a blinded manner to ensure unbiased results. The study will take place across three hospitals in Oman from February 2022 to August 2024, focusing on patients experiencing significant vertigo symptoms. The goal is to identify the most effective treatment with the least side effects for this common condition.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 60 who present with acute peripheral vertigo and associated nausea or vomiting.
Not a fit: Patients over 60 years old or those with central causes of vertigo or other significant health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment options for patients suffering from acute peripheral vertigo, enhancing their recovery experience.
How similar studies have performed: Other studies have explored similar treatment comparisons for vertigo, but this specific combination of medications in a triple-blind format is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * □ Acute peripheral vertigo with nausea or vomiting (vas, visual analog scale \>5) during their emergency department episode of care for which the attending physician recommending antiemetic, onset with in 3 days . * Age( 18- 60). Exclusion Criteria: * • Age \>60. * Any organic brain disease (Clear central cause; "malignancy with brain metastasis".) * History of epilepsy * Pregnancy. * Dementia, Parkinson's disease * Abnormal vital signs * Any known drug allergy to the study drugs * Undergoing chemotherapy or radiotherapy * Mechanical bowel obstruction or perforation, gastrointestinal bleeding * Inability to understand study explanation or outcome measures (any reason) * Patients who refused to participate study.
Where this trial is running
Muscat
- Al Nahdha hospital, AFH and Sohar hospital — Muscat, Oman (RECRUITING)
Study contacts
- Principal investigator: Asma Al Buraiki, MD — Oman Medical Speciality Board
- Study coordinator: Asma Al Buraiki, MD
- Email: asma.b19@resident.omsb.org
- Phone: +96896735469
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Peripheral Vertigo, ED, vertigo, metoclopramide, promethazine, Prochlorperazine